News

AstraZeneca arthritis drug has mixed results in Phase III trial

LONDON (Reuters) – AstraZeneca’s experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.
It achieved a statistically significant improvement in a test assessing signs and sy…

LONDON (Reuters) – AstraZeneca’s experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.

It achieved a statistically significant improvement in a test assessing signs and symptoms of the disease, but failed to show an improvement in an X-ray endpoint, according to results from the OSKIRA-1 Phase III study.

(Reporting by Ben Hirschler)

Topics